Currently out of the existing stock ratings of David Hoang, 52 are a BUY (74.29%), 13 are a HOLD (18.57%), 5 are a SELL (7.14%).

David Hoang

Work Performance Price Targets & Ratings Chart

Analyst David Hoang, currently employed at DEUTSCHE BANK, carries an average stock price target met ratio of 65% that have a potential upside of 37.28% achieved within 243 days.

David Hoang’s has documented 131 price targets and ratings displayed on 18 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on DNLI, Denali Therapeutics at 16-Jul-2026.

Wall Street Analyst David Hoang

Analyst best performing recommendations are on MLNT (MELINTA THERAPEUTICS).
The best stock recommendation documented was for SYRE (SPYRE THERAPEUTICS) at 9/26/2025. The price target of $43 was fulfilled within 147 days with a profit of $26.76 (164.78%) receiving and performance score of 11.21.

Average potential price target upside

of $51.87 (30.25%) on PRAX (PRAXIS PRECISION MEDICINES ).
of $50.09 (62.8%) on AXSM (AXSOME THERAPEUTICS).
of $34.23 (25.24%) on JAZZ (JAZZ PHARMACEUTICALS PLC).

ORTX Orchard Therapeutics PLC ALLK Allakos GOSS Gossamer Bio MLNT Melinta Therapeutics PRVB Provention Bio SRPT Sarepta Therapeutics NBIX Neurocrine Biosciences ACAD ACADIA Pharmaceuticals LBPH Longboard Pharmaceuticals AXSM Axsome Therapeutics DNLI Denali Therapeutics HRMY Harmony Biosciences Holdings XENE Xenon Pharmaceuticals ALKS Alkermes Plc JAZZ Jazz Pharmaceuticals PLC PRAX Praxis Precision Medicines SAGE Sage Therapeutic SYRE Spyre Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Dae Gon Ha (STIFEL)